Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
UBS
Accenture
Queensland Health
AstraZeneca
Baxter
Boehringer Ingelheim
Fuji
McKinsey
QuintilesIMS

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,916,485

« Back to Dashboard

Which drugs does patent 6,916,485 protect, and when does it expire?

Patent 6,916,485 protects ORAVIG and is included in one NDA.

This patent has twenty patent family members in fourteen countries.
Summary for Patent: 6,916,485
Title: Prolonged release bioadhesive therapeutic systems
Abstract:The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active dissolution test of more than 70% over 8 hours and to a method for its preparation. The bioadhesive therapeutic system may be in tablet form and may contain quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of the tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and may contain between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.
Inventor(s): Aiache; Jean-Marc (Paris, FR), Costantini; Dominique (Paris, FR), Chaumont; Christine (Paris, FR)
Assignee: Bioalliance Pharma (Paris, FR)
Application Number:10/307,938
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Process; Use;

Drugs Protected by US Patent 6,916,485

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Midatech Pharma Us ORAVIG miconazole TABLET;BUCCAL 022404-001 Apr 16, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF OROPHARYNGEAL CANDIDIASIS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,916,485

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France01 09811Jul 23, 2001

Non-Orange Book US Patents Family Members for Patent 6,916,485

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,651,698 Prolonged release bioadhesive therapeutic systems ➤ Sign Up
8,518,442 Prolonged release bioadhesive therapeutic systems ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,916,485

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 373464 ➤ Sign Up
Austria 411003 ➤ Sign Up
Canada 2455633 ➤ Sign Up
China 101524337 ➤ Sign Up
China 1547464 ➤ Sign Up
Cyprus 1107828 ➤ Sign Up
Cyprus 1108796 ➤ Sign Up
Germany 60222557 ➤ Sign Up
Germany 60229456 ➤ Sign Up
Denmark 1408911 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Federal Trade Commission
QuintilesIMS
Baxter
McKinsey
Johnson and Johnson
Fish and Richardson
Queensland Health
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot